|
|
 |
|
|
|
 |
| Market Cap | 1.12B | EPS (ttm) | -1.32 |
| P/E | - | EPS this Y | -116.70% |
| Forward P/E | - | EPS next Y | -8.60% |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 2.86 | EPS Q/Q | -24.90% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 0.40% | Inst Own | 79.00% |
| Insider Trans | 0.00% | Inst Trans | 4.75% |
| Short Float | 14.95% | Earnings | Aug 11/a |
| Analyst Recom | 1.80 | Target Price | 22.40 |
| Avg Volume | 381.94K | 52W Range | 4.51 - 23.50 |
|
|
|
|
| Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California. |
|
|
 |
| Market Cap | 277.46M | EPS (ttm) | -0.59 |
| P/E | - | EPS this Y | 74.30% |
| Forward P/E | 36.24 | EPS next Y | 172.40% |
| PEG | - | EPS past 5Y | 24.00% |
| P/S | 0.97 | EPS next 5Y | - |
| P/B | 7.69 | EPS Q/Q | 139.30% |
| Dividend | - | Sales Q/Q | 14.70% |
| Insider Own | 0.60% | Inst Own | 88.40% |
| Insider Trans | 0.00% | Inst Trans | 3.64% |
| Short Float | 2.81% | Earnings | Aug 09/a |
| Analyst Recom | 2.10 | Target Price | 11.50 |
| Avg Volume | 373.46K | 52W Range | 4.21 - 10.45 |
|
|
|
|
| PlayAGS, Inc. designs and supplies gaming products and services for the gaming industry in the United States and internationally. It operates through three segments: Electronic Gaming Machines (EGM), Table Products, and Interactive Games (Interactive). The EGM segment offers various video slot titles for the marketplace; and EGM cabinets, including the Orion Starwall, Orion Curve Premium, Big Red, Orion Portrait, Orion Slant, Orion Curve, Orion Upright, and ICON. This segment also provides conversion kits that allow existing game titles to be converted to other game titles offered within that operating platform. It serves Class II Native American and Mexico, as well as Class III Native American, commercial, and charitable jurisdictions. The Table Products segment offers table products, including live felt table games, side bet offerings, progressives, card shufflers, signage, and other ancillary table game equipment, as well as table technology related to blackjack, poker, baccarat, craps, and roulette. This segment also provides Dex S, a single deck card shuffler for poker tables. Its brands include In Bet, Buster Blackjack, Double Draw Poker, and Criss Cross Poker. The Interactive segment offers a platform for business-to-business content aggregation used by real-money gaming and sports-betting partners; and business-to-consumer social casino games through its mobile app, Lucky Play Casino. The company was formerly known as AP Gaming Holdco, Inc. and changed its name to PlayAGS, Inc. in December 2017. PlayAGS, Inc. was incorporated in 2005 and is headquartered in Las Vegas, Nevada. |
|
|
 |
| Market Cap | 15.33M | EPS (ttm) | -1.41 |
| P/E | - | EPS this Y | -42.40% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 7.30% |
| P/S | 0.25 | EPS next 5Y | - |
| P/B | - | EPS Q/Q | 49.80% |
| Dividend | - | Sales Q/Q | 0.00% |
| Insider Own | 1.60% | Inst Own | 28.00% |
| Insider Trans | -43.92% | Inst Trans | -2.26% |
| Short Float | 0.25% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 83.51K | 52W Range | 1.51 - 3.39 |
|
|
|
|
| Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Campbell Kerry G. | Director | Sep 06 | Sale | 2.23 | 76,890 | 171,465 | 3,000 | Sep 07 05:07 PM | | Campbell Kerry G. | Director | Aug 30 | Sale | 2.02 | 20,110 | 40,622 | 79,890 | Aug 31 05:00 PM |
|
|
| |
 |
| Market Cap | 17.85M | EPS (ttm) | -2.61 |
| P/E | - | EPS this Y | 37.90% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 27.10% |
| P/S | - | EPS next 5Y | - |
| P/B | 2.47 | EPS Q/Q | 61.60% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | - | Inst Own | 1.00% |
| Insider Trans | - | Inst Trans | -23.36% |
| Short Float | - | Earnings | - |
| Analyst Recom | 2.00 | Target Price | 15.00 |
| Avg Volume | 162.63K | 52W Range | 0.81 - 9.59 |
|
|
|
|
| Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France. |
|
|
 |
| Market Cap | 52.52M | EPS (ttm) | -3.48 |
| P/E | - | EPS this Y | 17.50% |
| Forward P/E | - | EPS next Y | 34.10% |
| PEG | - | EPS past 5Y | -6.20% |
| P/S | 5.31 | EPS next 5Y | 36.90% |
| P/B | 1.31 | EPS Q/Q | -39.00% |
| Dividend | - | Sales Q/Q | -60.80% |
| Insider Own | 16.03% | Inst Own | 59.40% |
| Insider Trans | 1.86% | Inst Trans | 3.23% |
| Short Float | 1.38% | Earnings | Aug 10/a |
| Analyst Recom | 2.50 | Target Price | 9.75 |
| Avg Volume | 2.46M | 52W Range | 0.68 - 19.87 |
|
|
|
|
| Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Shukla Sath | Chief Financial Officer | Aug 29 | Sale | 0.89 | 6,017 | 5,378 | 56,064 | Aug 30 05:00 PM | | Aquilo Capital Management, LLC | 10% Owner | Apr 26 | Buy | 5.24 | 39,727 | 207,971 | 5,321,231 | Apr 28 04:13 PM | | Aquilo Capital Management, LLC | 10% Owner | Mar 30 | Buy | 8.79 | 50,000 | 439,420 | 5,281,504 | Mar 31 03:51 PM | | Aquilo Capital Management, LLC | 10% Owner | Mar 14 | Buy | 7.63 | 23,708 | 180,797 | 5,231,504 | Mar 16 04:23 PM | | Aquilo Capital Management, LLC | 10% Owner | Feb 28 | Buy | 9.53 | 44,833 | 427,227 | 5,207,796 | Mar 02 03:52 PM |
|
|
| |
 |
| Market Cap | 506.37M | EPS (ttm) | 0.77 |
| P/E | 4.77 | EPS this Y | -991.10% |
| Forward P/E | - | EPS next Y | 40.00% |
| PEG | - | EPS past 5Y | - |
| P/S | 4.67 | EPS next 5Y | - |
| P/B | 2.30 | EPS Q/Q | 102.30% |
| Dividend | - | Sales Q/Q | 45.20% |
| Insider Own | 4.80% | Inst Own | 63.00% |
| Insider Trans | 0.00% | Inst Trans | 4.96% |
| Short Float | 0.87% | Earnings | Aug 10/b |
| Analyst Recom | 2.00 | Target Price | 5.67 |
| Avg Volume | 322.49K | 52W Range | 1.62 - 10.00 |
|
|
|
|
| Innovid Corp. operates an independent software platform that provides ad serving and creative services. The company offers advertising services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV, and desktop TV environments to advertisers, publishers, and media agencies. It also provides creative management; advertising measurement; identity resolution; and publisher solutions. The company serves consumer packaged goods, pharmaceutical and healthcare, financial services, and automotive and technology industries; third party agencies; and publishers in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Innovid Corp. was incorporated in 2007 and is headquartered in New York, New York. |
|
|
 |
| Market Cap | 9.70B | EPS (ttm) | -3.03 |
| P/E | - | EPS this Y | -105.20% |
| Forward P/E | - | EPS next Y | 31.00% |
| PEG | - | EPS past 5Y | -33.20% |
| P/S | 3.26 | EPS next 5Y | - |
| P/B | 3.30 | EPS Q/Q | -128.00% |
| Dividend | - | Sales Q/Q | 29.60% |
| Insider Own | 3.27% | Inst Own | 31.60% |
| Insider Trans | 0.00% | Inst Trans | -15.97% |
| Short Float | 9.93% | Earnings | Sep 08/b |
| Analyst Recom | 1.80 | Target Price | 41.25 |
| Avg Volume | 5.39M | 52W Range | 14.93 - 89.80 |
|
|
|
|
| Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, and live broadcasting. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China. |
|
| |
 |
| Market Cap | 63.41M | EPS (ttm) | - |
| P/E | - | EPS this Y | - |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | 0.17 | EPS next 5Y | - |
| P/B | 0.15 | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | -10.70% |
| Insider Own | - | Inst Own | 0.01% |
| Insider Trans | - | Inst Trans | - |
| Short Float | - | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 2.00M | 52W Range | 1.50 - 4.66 |
|
|
|
|
| Graphex Group Limited engages in the development, manufacturing, and marketing of graphene products in the People's Republic of China. The company operates through three segments: Manufacturing and Sale of Graphene Products; Landscape Design; and Catering. It provides natural spherical graphite to produce anodes for Li-ion batteries used in electric vehicles; high purity graphite for use in refractory materials and advanced coatings, and other products; and synthetic graphite. The company also offers landscape architecture services and activities. In addition, it provides catering and interior design and landscape architecture services; and invests in food industry; and focuses on the operation of restaurants. The company was formerly known as Earthasia International Holdings Limited and changed its name to Graphex Group Limited in April 2021. Graphex Group Limited was founded in 1981 and is headquartered in Causeway Bay, Hong Kong. |
|
|
 |
| Market Cap | 49.14M | EPS (ttm) | -0.17 |
| P/E | - | EPS this Y | 20.00% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | 16.08 | EPS next 5Y | - |
| P/B | - | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | 1075.00% |
| Insider Own | - | Inst Own | 2.40% |
| Insider Trans | - | Inst Trans | - |
| Short Float | 3.97% | Earnings | - |
| Analyst Recom | - | Target Price | 7.50 |
| Avg Volume | 6.75M | 52W Range | 1.26 - 29.70 |
|
|
|
|
| Sidus Space, Inc., a space-as-a-service company, engages in the design, manufacture, launch, and data collection of commercial satellite worldwide. Its services include satellite manufacturing; precision manufacturing, assembly, and test; low earth orbit microsatellite; payload integrations; launch and support services; space-based data services and analytics; precision computer numerical control machining and fabrication; Swiss screw machining; wire cable harness fabrication; 3D composite and metal printing; and satellite deployment and microgravity testing and research services, as well as services related to electrical and electronic assemblies. The company also offers hardware solutions consisting of an external flight test platform to develop, test, and fly experiments, as well as delivers hardware, materials, and advanced electronics on the international space station; and space station integrated kinetic launcher for orbital payload systems. It serves commercial space, aerospace, defense, underwater marine, and other commercial and government customers. The company was founded in 2014 and is headquartered in Merritt Island, Florida. Sidus Space, Inc. is a subsidiary of Craig Technical Consulting, Inc. |
|
|
 |
| Market Cap | 432.25M | EPS (ttm) | 3.36 |
| P/E | 7.06 | EPS this Y | 330.90% |
| Forward P/E | 4.88 | EPS next Y | 13.66% |
| PEG | 0.71 | EPS past 5Y | 39.60% |
| P/S | 0.67 | EPS next 5Y | 10.00% |
| P/B | 3.20 | EPS Q/Q | 22.40% |
| Dividend | - | Sales Q/Q | 26.20% |
| Insider Own | 2.30% | Inst Own | 92.10% |
| Insider Trans | 0.00% | Inst Trans | -0.39% |
| Short Float | 3.32% | Earnings | Sep 08/b |
| Analyst Recom | 2.20 | Target Price | 34.60 |
| Avg Volume | 84.15K | 52W Range | 20.25 - 29.69 |
|
|
|
|
| MasterCraft Boat Holdings, Inc., through its subsidiaries, designs, manufactures, and markets recreational powerboats. It operates through three segments: MasterCraft, NauticStar, and Crest. The MasterCraft segment produces recreational performance sport boats and luxury day boats under the MasterCraft and Aviara brands, which are used for water skiing, wakeboarding, and wake surfing, as well as general recreational boating. The NauticStar segment offers boats that are primarily used for saltwater fishing and general recreational boating. The Crest segment produces pontoon boats for use in general recreational boating. The company also offers ski/wake, outboard, and sterndrive boats, as well as various accessories, including trailers and aftermarket parts. It sells its boats under the MasterCraft, NauticStar, Crest, and Aviara brands through a network of independent dealers in North America and internationally. The company was formerly known as MCBC Holdings, Inc. and changed its name to MasterCraft Boat Holdings, Inc. in November 2018. MasterCraft Boat Holdings, Inc. was founded in 1968 and is based in Vonore, Tennessee. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Campion Donald C | Director | Oct 18 | Sale | 26.47 | 4,641 | 122,847 | 13,246 | Oct 19 04:23 PM | | Campion Donald C | Director | Oct 12 | Sale | 26.46 | 2,069 | 54,746 | 17,887 | Oct 13 04:05 PM | | Campion Donald C | Director | Oct 11 | Sale | 26.40 | 2,844 | 75,082 | 19,956 | Oct 12 04:08 PM |
|
|
|
|
1234567next
|
|
|